文献速递青光眼小儿眼科与斜弱视角膜与眼表疾病

无虹膜继发青光眼:引流装置与小梁切除术联合MMC的疗效比较

Outcomes of Glaucoma Drainage Device Implantation and Trabeculectomy With Mitomycin C in Glaucoma Secondary to Aniridia.
PubMed 文献 · Am J Ophthalmol · 2021-03-15

这项回顾性比较干预病例系列研究纳入了30例先天性无虹膜继发青光眼患者,比较Aurolab房水引流装置(AADI)植入与小梁切除术联合丝裂霉素C(MMC)的疗效。结果显示AADI组2年失败累积概率为11.1%,显著低于小梁切除术组的58.3%(P=.05),且AADI组2年眼压更低(14.1±2.8 vs 19.6±6.6 mm Hg,P=.02)。小梁切除术组白内障手术需求更高(42% vs 0%,P=.01)。

要点

  • AADI植入2年失败累积概率11.1%,低于小梁切除术联合MMC的58.3%(P=.05)
  • AADI组2年眼压14.1±2.8 mm Hg,低于小梁切除术组的19.6±6.6 mm Hg(P=.02)
  • 小梁切除术组42%患者需白内障手术,AADI组无此需求(P=.01)

核心结论

  • 在无虹膜继发青光眼患者中,AADI植入相比小梁切除术联合MMC能获得更低的眼压和更高的手术成功率。
  • 小梁切除术联合MMC后白内障摘除需求更常见。

研究设计与样本

  • 回顾性比较干预病例系列研究,纳入30例先天性无虹膜继发青光眼患者的30只眼。
  • 18只眼接受AADI植入,12只眼接受小梁切除术联合MMC。
  • 手术失败定义为眼压>21 mm Hg或较基线下降<20%、眼压≤5 mm Hg、因青光眼或并发症再手术、或丧失光感视力。

主要发现

  • AADI组2年失败累积概率为11.1%(95%CI=2.9%-37.6%),小梁切除术组为58.3%(95%CI=33.5%-84.8%),P=.05(log-rank)。
  • 2年时AADI组眼压为14.1±2.8 mm Hg,小梁切除术组为19.6±6.6 mm Hg,P=.02。
  • 2年时AADI组青光眼用药数量为1.7±0.9,小梁切除术组为2.2±0.8,P=.25。
  • 每组各有1例患者出现手术并发症(P=.65)。
  • 小梁切除术组有5例(42%)患者行白内障手术,AADI组无患者行白内障手术(P=.01)。

临床怎么用

  • 对于无虹膜继发青光眼,AADI植入可作为优先考虑的手术方式之一,以降低失败率和眼压。
  • 选择小梁切除术联合MMC时需告知患者术后白内障手术风险较高。

局限性

  • 回顾性设计,样本量较小(共30只眼),可能存在选择偏倚。
  • 原文未报告随访时长等其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the outcomes of Aurolab aqueous drainage implant (AADI; Aurolab) placement and trabeculectomy with mitomycin C (MMC) in patients with glaucoma secondary to aniridia. DESIGN: Retrospective comparative interventional case series. METHODS: This study included patients with congenital aniridia who underwent AADI implantation or trabeculectomy with MMC. Surgical failure was defined as IOP > 21 mm Hg or reduced <20% from baseline, IOP ≤ 5 mm Hg, reoperation for glaucoma or a complication, or loss of light perception vision. RESULTS: A total of 30 eyes of 30 patients underwent surgical treatment, including 18 eyes that received an AADI and 12 eyes that had a trabeculectomy with MMC. The cumulative probability of failure at 2 years was 11.1% (95% CI = 2.9%-37.6%) in the AADI group and 58.3% (95% CI = 33.5%-84.8%) in the trabeculectomy group (P = .05, log-rank). At 2 years, IOP (mean ± SD) was 14.1 ± 2.8 mm Hg in the AADI group and 19.6 ± 6.6 mm Hg in the trabeculectomy group (P = .02), and the number of glaucoma medications was 1.7 ± 0.9 in the AADI group and 2.2 ± 0.8 in the trabeculectomy group (P = .25). Surgical complications developed in 1 patient in each treatment group (P = .65). Cataract surgery was performed in 5 (42%) patients in the trabeculectomy group and no patients in the AADI group (P = .01). CONCLUSIONS: Placement of an AADI resulted in lower IOP and a higher rate of surgical success compared to trabeculectomy with MMC in eyes with glaucoma associated with aniridia. Cataract extraction was more frequently required after trabeculectomy with MMC than AADI implantation.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Durai I, Pallamparthy S, Puthuran GV, et al. Outcomes of Glaucoma Drainage Device Implantation and Trabeculectomy With Mitomycin C in Glaucoma Secondary to Aniridia. Am J Ophthalmol. 2021. PMID: 33737035. doi:10.1016/j.ajo.2021.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。